Peptidomimetic macrocycles
The present invention provides novel peptidomimetic macrocycles and methods of using such macrocycles for the treatment of disease.
1. A peptidomimetic macrocycle comprising an amino acid sequence which is at least 60% identical to the amino acid sequence of: SEQ ID NO. 163.
2. The peptidomimetic macrocycle of claim 1 , wherein the peptidomimetic macrocycle comprises an amino acid sequence which is at least 80% identical to the amino acid sequence of: SEQ ID NO. 163.
3. The peptidomimetic macrocycle of claim 1 , wherein the peptidomimetic macrocycle comprises an amino acid sequence which is at least 90% identical to the amino acid sequence of: SEQ ID NO. 163.
4. The peptidomimetic macrocycle of claim 1 , wherein the peptidomimetic macrocycle comprises an amino acid sequence which is at least 95% identical to the amino acid sequence of: SEQ ID NO. 163.
5. The peptidomimetic macrocycle of claim 1 , wherein the peptidomimetic macrocycle comprises an amino acid sequence which is: SEQ ID NO. 163.
6. The peptidomimetic macrocycle of claim 1 , wherein the peptidomimetic macrocycle comprises a helix.
7. The peptidomimetic macrocycle of claim 1 , wherein the peptidomimetic macrocycle comprises an α-helix.
8. The peptidomimetic macrocycle of claim 1 , wherein the peptidomimetic macrocycle comprises an α,α-disubstituted amino acid.
9. The peptidomimetic macrocycle of claim 1 , wherein the peptidomimetic macrocycle comprises a crosslinker linking the α-positions of at least two amino acids within the peptidomimetic macrocycle.
10. The peptidomimetic macrocycle of claim 9 , wherein at least one of the two amino acids is an α,α-disubstituted amino acid.
11. The peptidomimetic macrocycle of claim 1 , wherein the peptidomimetic macrocycle has the formula:
wherein:
each A, C, D, and E is independently a natural or non-natural amino acid, and each D and E independently optionally includes a capping group;
each B is independently a natural or non-natural amino acid, amino acid analog, or
each R 1 and R 2 is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl, unsubstituted or substituted with halo-;
each R 3 is independently hydrogen, alkyl, alkenyl, alkynyl, arylalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, cycloalkylalkyl, cycloaryl, or heterocycloaryl, optionally substituted with R 5 ;
each L is independently a macrocycle-forming linker of the formula -L 1 -L 2 -;
each L 1 and L 2 is independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, cycloarylene, heterocycloarylene, or [—R 4 —K—R 4 —], each optionally substituted with R 5 ;
each R 4 is independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene;
each K is independently O, S, SO, SO 2 , CO, CO 2 , or CONR 3 ;
each R 5 is independently halogen, alkyl, —OR 6 , —N(R 6 ) 2 , —SR 6 , —SOR 6 , —SO 2 R 6 , —CO 2 R 6 , a fluorescent moiety, a radioisotope or a therapeutic agent;
each R 6 is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkylalkyl, heterocycloalkyl, a fluorescent moiety, a radioisotope or a therapeutic agent;
each R 7 is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, cycloaryl, or heterocycloaryl, each optionally substituted with R 5 , or forms part of a cyclic structure with a D residue;
each R 8 is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, cycloaryl, or heterocycloaryl, each optionally substituted with R 5 , or forms part of a cyclic structure with an E residue;
each v and w is independently an integer from 1-1000;
u is an integer from 1-10;
each x, y and z is independently an integer from 0-10; and
each n is independently an integer from 1-5.
12. The peptidomimetic macrocycle of claim 11 , wherein L does not include a thioether or a triazole.
13. The peptidomimetic macrocycle of claim 1 , wherein the peptidomimetic macrocycle comprises a cross linker linking a backbone amino group of a first amino acid within the peptidomimetic macrocycle to a second amino acid within the peptidomimetic macrocycle.
14. The peptidomimetic macrocycle of claim 13 , wherein the peptidomimetic macrocycle has the formula (IV) or (IVa):
wherein:
each A, C, D, and E is independently a natural or non-natural amino acid, and each D and E independently optionally includes a capping group;
each B is independently a natural or non-natural amino acid, amino acid analog, or
each R 1 and R 2 is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl, each non-H group being unsubstituted or substituted with halo-, or part of a cyclic structure with an E residue;
each R 3 is independently hydrogen, alkyl, alkenyl, alkynyl, arylalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, cycloalkylalkyl, cycloaryl, or heterocycloaryl, each non-H group being optionally substituted with R 5 ;
each L 1 and L 2 is independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, cycloarylene, heterocycloarylene, or [—R 4 —K—R 4 —], each optionally substituted with R 5 ;
each R 4 is independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene;
each K is independently O, S, SO, SO 2 , CO, CO 2 , or CONR 3 ;
each R 5 is independently halogen, alkyl, —OR 6 , —N(R 6 ) 2 , —SR 6 , —SOR 6 , —SO 2 R 6 , —CO 2 R 6 , a fluorescent moiety, a radioisotope or a therapeutic agent;
each R 6 is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkylalkyl, heterocycloalkyl, a fluorescent moiety, a radioisotope or a therapeutic agent;
each R 7 is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, cycloaryl, or heterocycloaryl, optionally substituted with R 5 ;
each v and w is independently an integer from 1-1000;
u is an integer from 1-10;
each x, y and z is independently an integer from 0-10; and
each n is independently an integer from 1-5.
15. The peptidomimetic macrocycle of claim 14 , wherein L 1 and L 2 either alone or in combination do not include a thioether or a triazole.
16. The peptidomimetic macrocycle of claim 11 , wherein L 1 and L 2 are independently alkylene, alkenylene or alkynylene.
17. The peptidomimetic macrocycle of claim 11 , wherein L 1 and L 2 are independently C 3 -C 10 alkylene or C 3 -C 10 alkenylene.
18. The peptidomimetic macrocycle of claim 17 , wherein L 1 and L 2 are independently C 3 -C 6 alkylene or C 3 -C 6 alkenylene.
19. The peptidomimetic macrocycle of claim 11 , wherein R 1 and R 2 are H.
20. The peptidomimetic macrocycle of claim 11 , wherein R 1 and R 2 are independently alkyl.
21. The peptidomimetic macrocycle of claim 11 , wherein R 1 and R 2 are methyl.
22. A pharmaceutical composition comprising the peptidomimetic macrocycle of claim 1 .